2021 ADA Highlights: Landmark DAPA-CKD Trial in Kidney Disease: Extending the Benefits of SGLT2 Inhibitors to and Beyond Diabetic Neuropathy

July 14, 2021

0 Comments
Login to view comments. Click here to Login